PHARVARIS N.V. EO -12 (9EN) - Total Liabilities
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has total liabilities worth €30.18 Million EUR (≈ $35.28 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See PHARVARIS N.V. EO -12 working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
PHARVARIS N.V. EO -12 - Total Liabilities Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 9EN asset base.
PHARVARIS N.V. EO -12 Competitors by Total Liabilities
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Usha Martin Limited
NSE:USHAMART
|
India | Rs8.89 Billion |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
USA | $2.77 Billion |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
China | CN¥6.91 Billion |
|
FLEX LNG Ltd
NYSE:FLNG
|
USA | $1.89 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥4.08 Billion |
|
Molymet
SN:MOLYMET
|
Chile | CL$878.73 Million |
|
China Tianying Inc
SHE:000035
|
China | CN¥21.26 Billion |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
China | CN¥31.41 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down PHARVARIS N.V. EO -12's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PHARVARIS N.V. EO -12 balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PHARVARIS N.V. EO -12's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual total liabilities of PHARVARIS N.V. EO -12 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €30.18 Million ≈ $35.28 Million |
+27.81% |
| 2024-12-31 | €23.61 Million ≈ $27.61 Million |
+61.23% |
| 2023-12-31 | €14.65 Million ≈ $17.12 Million |
-20.72% |
| 2022-12-31 | €18.47 Million ≈ $21.60 Million |
+158.85% |
| 2021-12-31 | €7.14 Million ≈ $8.34 Million |
-- |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more